- Home
- TARS
as of 02-06-2026 2:10pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $77.13 | AVG Volume (30 days): | 518.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.51 - $85.25 | Next Earning Date: | 02-24-2026 |
| Revenue: | $366,100,000 | Revenue Growth: | 182.44% |
| Revenue Growth (this year): | 147.71% | Revenue Growth (next year): | 53.74% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -57536000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
Chief Human Resources Officer
Avg Cost/Share
$81.41
Shares
15,565
Total Value
$1,255,683.96
Owned After
23,393
President/CEO and Board Chair
Avg Cost/Share
$82.98
Shares
6,000
Total Value
$495,089.41
Owned After
858,548
Chief Human Resources Officer
Avg Cost/Share
$80.10
Shares
7,397
Total Value
$592,499.70
Owned After
23,393
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$79.50
Shares
2,078
Total Value
$165,201.00
Owned After
21,941
SEC Form 4
Director
Avg Cost/Share
$81.43
Shares
22,946
Total Value
$1,864,677.82
Owned After
136,286
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Jan 2, 2026 | Sell | $81.41 | 15,565 | $1,255,683.96 | 23,393 | |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 24, 2025 | Sell | $82.98 | 6,000 | $495,089.41 | 858,548 | |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Dec 16, 2025 | Sell | $80.10 | 7,397 | $592,499.70 | 23,393 | |
| Lin Elizabeth Yeu | TARS | Chief Medical Officer | Dec 16, 2025 | Sell | $79.50 | 2,078 | $165,201.00 | 21,941 | |
| LINK WILLIAM J PHD | TARS | Director | Dec 15, 2025 | Sell | $81.43 | 22,946 | $1,864,677.82 | 136,286 |
Compare TARS vs Leading Stocks
See how TARS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.